Neogenomics Inc(NEO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.4 | Insider Own | 1.92% | Shs Outstand | 127.9M | Perf Week | 1.21% |
| Market Cap | 2.26B | Forward P/E | 52.07 | EPS next Y | 85.08% | Insider Trans | -1.23% | Shs Float | 126.0M | Perf Month | 6.53% |
| Enterprise Value | 2.57B | PEG | 0.91 | EPS next Q | 0.05 | Inst Own | 113.67% | Short Float | 12.6% | Perf Quarter | 56.12% |
| Income | -0.05B | P/S | 2.95 | EPS this Y | 52.27% | Inst Trans | 9.77% | Short Ratio | 5.59 | Perf Half Y | 105.96% |
| Sales | 0.77B | P/B | 2.87 | EPS next 5Y | 57.44% | ROA | -3.78% | Short Interest | 15.88M | Perf YTD | 49.74% |
| Book/sh | 6.14 | P/C | 15.55 | EPS past 3/5Y | 10.12% - | ROE | -6.33% | 52W High | -10.88% ($19.76) | Perf Year | 135.43% |
| Cash/sh | 1.13 | P/FCF | - | Sales past 3/5Y | 12.58% 10.35% | ROIC | -4.22% | 52W Low | 149.26% ($7.07) | Perf 3Y | 29.58% |
| Dividend Est. | - | EV/EBITDA | 220.76 | EPS Y/Y TTM | 50.58% | Gross Margin | 41.74% | Volatility(W/M) | 4.8% 4.41% | Perf 5Y | -66.47% |
| Dividend TTM | - | EV/Sales | 3.35 | Sales Y/Y TTM | 11.19% | Oper. Margin | -7.03% | ATR (14) | 0.8 | Perf 10Y | 115.15% |
| Dividend Ex-Date | - | Quick Ratio | 3.34 | EPS Q/Q | 104.85% | Profit Margin | -6.77% | RSI (14) | 59.83 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.6 | Sales Q/Q | 11.21% | SMA20 | 2.91% ($17.11) | Beta | 1.79 | Target Price | $19.72 |
| Payout | - | Debt/Eq | 0.57 | Earnings | 2026/7/28 | SMA50 | 11.35% ($15.81) | Rel Volume | 0.39 | Prev Close | $17.66 |
| Employees | 2500 | LT Debt/Eq | 0.56 | EPS/Sales Surpr. | 49.25% 2.4% | SMA200 | 49.59% ($11.77) | Avg Volume(3M) | 2.84M | Price | $17.61 |
| IPO | 1999/11/10 | Option/Short | Yes/Yes | Trades | 13101 | Volume | 1,110,725 | Change | -0.28% |
Company
NEO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🔬 NeoGenomics (NEO) is a specialty clinical laboratory company focused on cancer diagnostics. It operates a cancer genetics and molecular diagnostic testing network in the United States and the United Kingdom, offering physicians, hospitals, and pharmaceutical companies a broad test menu spanning solid tumors, hematologic malignancies, and hereditary cancers. With a two-pronged focus on clinical testing and advanced diagnostics, the company is strengthening its position in the precision oncology market.
Over the past 1 year, on the higher side
11% below its 1-year high.
NEO has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +52.3% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +29.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 113.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
FBT 0.05%
XHS 0.02%
TINT 0.02%
WDIG 0.01%
ACVT 0.01%It ranks #4 in the industry
Based on market cap of $2B.
NEO $2B PER -
TMO $223B PER 32.5
DHR $141B PER 35.6
NTRA $47B PER -
FAQ
What kind of company is NEO?
NEO belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of NEO?
The market cap of NEO is approximately $2.3B, ranking 1,997 within its sector.
What is the 52-week high and low for NEO?
NEO has recorded a 52-week high of $19.76 and a low of $7.07.
